SCHEMBL148479

SCHEMBL148479

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4[N+](=O)[O-])cc32)c(C)c1C(=O)NCCn1ccnn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 13/20 0.51
KDR P35968 11/20 0.51
FGFR1 P11362 9/20 0.51
PRKAA1 Q13131 7/20 0.49
PRKAA2 P54646 6/20 0.49
TLK2 Q86UE8 3/20 0.49
HDAC3 O15379 3/20 0.48
HDAC4 P56524 3/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC7 Q8WUI4 3/20 0.48
HDAC2 Q92769 3/20 0.48
HDAC10 Q969S8 3/20 0.48
HDAC11 Q96DB2 3/20 0.48
HDAC8 Q9BY41 3/20 0.48
HDAC6 Q9UBN7 3/20 0.48
HDAC9 Q9UKV0 3/20 0.48
HDAC5 Q9UQL6 3/20 0.48
EGFR P00533 3/20 0.46
LRRK2 Q5S007 2/20 0.46
PLK4 O00444 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144561 0.91 PDGFRB (0.56) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL144568 0.89 KDR (0.55) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL144942 0.85 KDR (0.66) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL6272302 0.83 ALK (0.57) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL146207 0.80 MET (0.65) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL144979 0.78 KDR (0.71) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL144186 0.77 FGFR1 (0.55) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL13711988 0.77 KDR (0.66) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL142344 0.77 KDR (0.61) PDGFRBKDRFGFR1PRKAA1PRKAA2
SCHEMBL146649 0.77 PDGFRB (0.41) PDGFRBKDRFGFR1PRKAA1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 PDGFRB 467/4885KDR 1077/4885FGFR1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.